NEUROLOGY 2006;67:1262-1264
© 2006 American Academy of Neurology
Brief Communications
Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial
A. Bender, MD, W. Koch,

Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT

http://neurology.org/cgi/content/abs.../7/1262?ck=nck